Quick answer: AOD-9604 produced promising results in some animal studies, but the largest human trial did not show a meaningful weight-loss benefit over placebo. That trial tested a daily tablet, not the injectable form often discussed online. The human safety data are more reassuring than the efficacy data, but they come from company-run trials, and the published safety review was company-funded.

For anyone asking does AOD-9604 work, or searching for AOD-9604 results, the evidence needs to be separated by species, formulation and outcome. A purity result cannot fill gaps in clinical evidence.

What the animal studies found

In obese Zucker rats, oral AOD-9604 given for 19 days was associated with 15.8 g of weight gain, compared with 35.6 g in controls. That is a clear preclinical signal in this model, but it is a short animal study, not proof of weight loss in people. Ng et al., Hormone Research (2000).

A separate obese-mouse study reported that the effect was absent in mice lacking the beta-3 adrenergic receptor. This gives researchers a clue about a possible biological pathway; it does not establish a treatment effect in humans. Heffernan et al., Endocrinology (2001).

The two oral trials: an early signal, then a larger negative result

The 2004 study: a result that needed confirmation

A company-run, 12-week trial in around 300 adults tested oral AOD-9604 tablets at several doses. The company’s reported figures put the 1 mg group at about 0.22 kg of weight loss per week, compared with around 0.07 kg per week for placebo. The dose-response pattern was inverted: the higher doses did not perform better. The study was not published as a full peer-reviewed journal article; the available account is a conference abstract and related company material. The company said the result fell short of statistical significance overall. Study record, University of Queensland repository; FDA briefing document, 4 December 2024.

A frequently repeated subgroup hint concerned 149 women who had lost less than 2 kg during a run-in period. In that subgroup, the 0.5 mg arm reportedly lost about 3.1 kg, versus 0.8 kg on placebo. But each dose subgroup contained only about 37 people, and the 1 mg arm in the same subgroup reportedly lost only about 1.2 kg. This is exploratory, underpowered evidence, not a reliable efficacy result. At most, it could have supported a further trial.

OPTIONS: what the 502-person trial actually showed

The larger OPTIONS Phase 2B trial enrolled 502 adults with obesity across 16 Australian sites. Participants had a mean starting weight of about 106 kg and were assigned, double-blind, to daily oral tablets containing 0.25, 0.5 or 1 mg AOD-9604, or placebo, for 24 weeks.

The key comparison is not whether participants lost weight. It is whether AOD-9604 added a meaningful benefit beyond the trial’s diet-and-exercise programme. The placebo group lost about 3.5 kg during the trial. The AOD-9604 groups lost roughly 3.5–4.2 kg, based on the sponsor’s chart. These are close outcomes, not a convincing separation. The trial was designed to detect a 1.8 kg difference between treatment and placebo and did not find one. The sponsor reported no relevant findings for waist circumference, body fat, glucose or cholesterol, and concluded: “Development of the drug for this condition is terminated.”

The trial’s context matters, too. The placebo group lost around 6 kg over approximately seven months: about 2.3 kg during a four-week run-in, followed by 3.5 kg during the trial. Participants had dietitian-led diet and exercise support. The clearest practical finding is that the structured programme was associated with weight loss; AOD-9604 did not demonstrate an additional, statistically meaningful benefit over placebo.

The OPTIONS results were announced by the company, not published as a peer-reviewed journal paper. Metabolic Pharmaceuticals ASX announcement, 21 February 2007.

A critical limitation: tablet results are not injection results

Both obesity trials tested tablets. They do not establish the efficacy of an injection. In its December 2024 review, the US Food and Drug Administration (FDA) reported that it had found no human study of injected or cream AOD-9604. The closest human evidence was a small intravenous study involving 23 people: participants lost about 0.58 kg over three weeks, with no significant difference from placebo. That is not evidence that an injection sold or promoted elsewhere will produce weight loss.

The FDA’s Pharmacy Compounding Advisory Committee voted 12–0 against adding AOD-9604 to the 503A compounding list on 4 December 2024. This was an advisory committee decision in the US, not a UK regulatory ruling. The FDA also raised concerns that impurities in compounded injectable peptides may trigger immune reactions. FDA briefing document; FDA PCAC meeting summary.

What the safety data do, and do not, say

Safety is the stronger side of the human evidence. A review by Stier, Vos and Kenley describes six company-run placebo-controlled trials involving around 900 people. The authors reported no rise in IGF-1, no worsening of blood sugar measures and side effects broadly comparable with placebo. These findings are reassuring within the limits of the studies. However, the review was company-funded, and tolerability in trials does not establish that a compound is effective or suitable for unsupervised use. Stier et al., Journal of Endocrinology and Metabolism (2013).

A separate cartilage claim also needs careful boundaries. The evidence cited here is a study of 32 rabbits with induced knee osteoarthritis, treated with intra-articular injections. It is animal research, not evidence that AOD-9604 treats joint pain or cartilage disease in people. Kwon & Park, Annals of Clinical & Laboratory Science (2015).

UK research and sports context

AOD-9604 is not a UK-licensed medicine. It is also prohibited under the World Anti-Doping Agency’s rules; WADA stated in 2013 that it was a non-approved substance, and AOD-9604 remains listed in the prohibited-substance framework. Researchers and athletes should check the current rules that apply to them. WADA statement, 22 April 2013.

UK medicines law restricts the sale or supply of unauthorised medicinal products and possession where there is an intention to supply them onward. The legal position depends on the product and circumstances; “research use only” is not permission to use a compound as a medicine. This article is not legal advice. Human Medicines Regulations 2012, regulation 46.

Purity is not proof of efficacy

A purity figure, even 99%+, is a quality and identity claim. It does not show that AOD-9604 causes weight loss, that a particular formulation works, or that it is safe for human use. These are different questions requiring different evidence.

At AXIOM Health, we offer AOD-9604 for research use only because researchers seek a clearly identified compound supported by batch-specific, third-party testing, not because the human evidence supports fat-loss claims. Please assess the batch documentation as well as the literature: our guides explain third-party testing and how to read a peptide COA. For broader research context, visit the AXIOM Research Compendium.

The most honest answer to “does AOD-9604 work?” is that animal findings are interesting, but the largest human trial did not show a meaningful benefit beyond diet and exercise. The tablet-to-injection gap remains unresolved. Researchers should keep those limits in view, and treat purity as a starting point for compound quality, not a substitute for efficacy evidence.